Can Meloxicam Be Added to Pregabalin and Nortriptyline?
Yes, meloxicam can be safely added to a patient already taking pregabalin and nortriptyline, as there are no known drug-drug interactions between these medications and emerging evidence suggests potential benefit from combining NSAIDs with neuropathic pain agents.
Drug Interaction Safety
The FDA label for pregabalin explicitly states that pregabalin does not inhibit or induce major cytochrome P450 enzymes and has no significant pharmacokinetic interactions with other medications 1. The nortriptyline FDA label lists only MAO inhibitors as contraindicated combinations, with no mention of NSAIDs or gabapentinoids 2. Meloxicam is metabolized primarily by CYP2C9 and CYP3A4, and pregabalin does not affect these pathways 1, 3.
Evidence for Combination Therapy
Guideline Support for Polypharmacy in Neuropathic Pain
The Mayo Clinic guidelines explicitly endorse combination therapy for neuropathic pain, noting that "2 or more medications are often used in combination to possibly achieve either an additive beneficial effect or a reduction in the adverse effects" 4. The guidelines specifically cite evidence that pregabalin added to existing analgesics (including in patients already on TCAs like nortriptyline) provided additional benefit comparable to pregabalin alone, suggesting "additional benefit was obtained when pregabalin was administered to patients already taking stable concomitant analgesics" 4.
Research Evidence for NSAID-Gabapentinoid Combinations
Research directly supports adding NSAIDs to gabapentinoid therapy:
Knee osteoarthritis study: The combination of meloxicam plus pregabalin showed significantly greater pain relief than either drug alone on VAS scores at 1,2, and 4 weeks, and on WOMAC scores at 4 weeks 5. This suggests that osteoarthritic pain involves both inflammatory and neuropathic components.
Preclinical evidence: Meloxicam combined with gabapentin demonstrated additive to synergistic antinociceptive effects in neuropathic pain models, with the specific ratio determining whether effects were additive or potentiated 6.
Clinical Algorithm for Adding Meloxicam
Verify no contraindications: Check for active GI ulceration, severe renal impairment (CrCl <30 mL/min), cardiovascular disease requiring caution with NSAIDs, or NSAID hypersensitivity.
Start meloxicam 7.5 mg daily: Use the lower starting dose, particularly in elderly patients or those with mild-moderate renal impairment.
Titrate to 15 mg daily if needed: After 1-2 weeks, increase to standard dose if pain control inadequate and no adverse effects.
Monitor for 4 weeks: Assess pain scores weekly; significant benefit should be apparent by 2-4 weeks based on the osteoarthritis trial 5.
Add gastroprotection if indicated: Consider PPI in patients >65 years, history of ulcers, or concurrent anticoagulation.
Important Caveats
Cardiovascular and renal monitoring: Meloxicam, despite being COX-2 preferential, still carries cardiovascular and renal risks similar to traditional NSAIDs 3. Monitor blood pressure and renal function, especially since the patient is already on nortriptyline (which can affect blood pressure).
Limited acute pain benefit: One trial in post-surgical pain found no advantage of meloxicam-gabapentin combination over gabapentin alone on day of surgery 7, suggesting the combination may be more effective for chronic rather than acute pain conditions.
Gabapentin-nortriptyline is already evidence-based: The existing combination of a gabapentinoid with nortriptyline has strong evidence, with one trial showing the combination superior to either drug alone for neuropathic pain 8. Adding meloxicam provides a third mechanism (COX inhibition) that may address any inflammatory component.
The combination is pharmacologically rational, addressing three distinct pain mechanisms: voltage-gated calcium channels (pregabalin), norepinephrine/serotonin reuptake (nortriptyline), and prostaglandin synthesis (meloxicam) 4, 9.